Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State or other jurisdiction of ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2019 Earnings Conference Call November 6, 2019 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joseph Ciaffoni - President and Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Jaffray David Steinberg - Jefferies & Company, Inc. Lachlan Hanbury-Brown - William Blair & Company Gregg Gilbert - SunTrust Robinson Humphrey Inc. Tian S ...

Table of Contents | --- | --- | --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------- ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2019 Results Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joe Ciaffoni - CEO Paul Brannelly - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Jaffray Greg Fraser - SunTrust Tian Sun - Needham & Company David Steinberg - Jefferies Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Kevin Kedra - G. Research Operator Good day, and welcome to the Q2 2019 C ...

Table of Contents | --- | --- | --- | --- | |----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joe Ciaffoni - CEO Paul Brannelly - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair David Amsellem - Piper Jaffray Gregg Gilbert - SunTrust David Steinberg - Jefferies Esther Hong - Janney Montgomery Kevin Kedra - G. Research Brandon Folkes - Cantor Fitzgerald Operator Good day, ladies and gentlemen, and welcome to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Table of Contents 04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. Securities registered pursuant Securities registered pursuant | --- | --- | --- | |---------- ...